Vir Biotechnology 거래 VIR

매도
 매수

VirBiotechnology 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

최신 뉴스

Frances Wang 2025 Apr 23, 16:00

Hang Seng Index Gains on Strong China GDP amid Trump Tariffs Uncertainty

Indices
Frances Wang 2025 Apr 23, 16:00

Forex news today: GBP/USD gains, USD/JPY declines, EUR/USD strengthens

Forex
Frances Wang 2025 Apr 23, 16:00

Trending stocks to watch: AMD, GOOG, NVDA, AMZN, MSFT

Stocks
Tommy Yap 2025 Apr 23, 16:00

Morning Note: Tariff Deadlock Grips US-China Trade; Alphabet's Report Looms; BOJ Dilemma

Morning Note Tech
Frances Wang 2025 Apr 22, 16:00

Commodity market today: Crude Oil Fluctuates as OPEC+ Modifies Production Goals

Commodities
Tommy Yap 2025 Apr 22, 16:00

Morning Note: Trump Calms Fed Fears; Tesla Disappoints; UK Trade Talks Begin

Morning Note Tech
Frances Wang 2025 Apr 21, 16:00

Stock Market Today: Dow, S&P 500, Nasdaq Fall as Trump Rips Fed Chair Powell

Stocks Indices
Tommy Yap 2025 Apr 21, 16:00

Morning Note: Trump's Fed Pressure Slams Stocks, Boosts Gold; Oil Recovers

Morning Note Stocks Commodities

정보

스프레드

0.07

스프레드(%)

1.1218 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

금요일

13:31 - 19:59

월요일

13:31-19:59

화요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

824242048

발행 주식 수

138064000

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-3.94

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments
Trustpilot